Original Research
Accepted on 30 Sep 2025
Cholesterol Metabolism Shapes Immune Low-Response States in LUAD: A Multi-Omics Cholesterol Metabolism Signature Predicts Immunotherapy Benefit and Identifies DHCR7 as a Therapeutic Target
in Cancer Immunity and Immunotherapy